A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager”. This type of immunotherapy ignites our own immune arsenal to fight cancer.
In the trial, which is still in progress and has not yet undergone peer-review, patients with advanced prostate cancer who had failed to respond to other treatments were given VIR-5500. Remarkably, initial findings showed that in the patients who received the highest doses, 82% saw reductions in their PSA (prostate specific antigen) levels – a commonly used measure of prostate cancer.
